Castle Biosciences Inc (NASDAQ:CSTL) disclosed that President and CEO Derek J. Maetzold sold a total of 4,400 shares of the company's common stock on March 26, 2026. The sales were executed at an average price of $25.551 per share, resulting in proceeds of $106,598. Following the transactions, the share price has moved lower to $23.53, a slide of 8.5% over the last week.
The disposition of shares occurred across multiple trades, with executed prices spanning from $25.050 to $25.955. In addition to the share sales, Maetzold exercised options to acquire 550 shares at an exercise price of $2.39, representing a gross exercise cost of $1,314.
Castle said the insider activity took place under a pre-arranged Rule 10b5-1 trading plan that the CEO established on December 3, 2025. The company did not provide additional commentary about the trades beyond the regulatory disclosure.
Valuation and market context
According to InvestingPro analysis cited with the company information, Castle's stock is trading below its Fair Value and is characterized as appearing undervalued. The same analysis notes a 39% decline in the share price year-to-date despite the company receiving a "GOOD" financial health score in that assessment.
Recent operating and clinical developments
Castle reported fourth-quarter 2025 financial results that surpassed analyst expectations on both the earnings and revenue lines. The company posted a diluted loss per share of $0.08, notably better than the forecasted loss of $0.32, which the disclosure quantifies as a 75% positive surprise. Revenue for the quarter totaled $87 million, exceeding the expected $77.09 million by 12.86%.
Following the earnings release, Canaccord Genuity reiterated a Buy rating on Castle and kept a $50 price target, pointing to robust revenue growth driven by increased test volumes as a rationale for its stance.
On the clinical front, Castle presented data at the American Academy of Dermatology Annual Meeting related to its DecisionDx-Melanoma assay. The analysis incorporated results from 1,868 patients with stage I-III cutaneous melanoma and demonstrated the test's capacity to stratify mortality risk. Those findings were derived from 22 Surveillance, Epidemiology, and End Results Program sites linked to patient test results.
What this sequence shows
The combination of insider selling under a Rule 10b5-1 plan, option exercises, valuation commentary from InvestingPro, and the company's recent operational and clinical disclosures paints a picture of active corporate and market engagement. The financial beats and clinical data highlight recent positive developments for Castle, while market pricing and the insider sale reflect ongoing investor reassessment of the stock.